Camurus AB News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

10.05.21	Camurus announces publication showing superior patient treatment satisfaction with Buvidal® weekly and monthly depot injections in opioid dependence (PR Newswire)
10.05.21	Camurus announces publication showing superior patient treatment satisfaction with Buvidal® weekly and monthly depot injections in opioid dependence (PR Newswire)
03.05.21	The Australian TGA approves key label updates to Buvidal® for treatment of opioid dependence (PR Newswire)
03.05.21	The Australian TGA approves key label updates to Buvidal® for treatment of opioid dependence (PR Newswire)
26.03.21	Camurus receives positive CHMP opinion for Buvidal 160mg monthly dose for the treatment of opioid dependence (PR Newswire)
26.03.21	Camurus receives positive CHMP opinion for Buvidal 160mg monthly dose for the treatment of opioid dependence (PR Newswire)
18.12.20	Swissmedic approves Buvidal for the treatment of opioid dependence (PR Newswire)
18.12.20	Swissmedic approves Buvidal for the treatment of opioid dependence (PR Newswire)
24.06.20	Positive Results From Phase 2 Study of Once-weekly FluidCrystal® Formulation of Setmelanotide in Healthy Volunteers With Obesity (PR Newswire)
23.06.20	Camurus Raises Full Year 2020 Revenue Guidance (PR Newswire)
23.06.20	Camurus Raises Full Year 2020 Revenue Guidance (PR Newswire)
01.06.20	Camurus Announces Submission of Request for Final Approval of Brixadi™ for the Treatment of Opioid Use Disorder in the US (PR Newswire)
01.06.20	Camurus Announces Submission of Request for Final Approval of Brixadi™ for the Treatment of Opioid Use Disorder in the US (PR Newswire)
14.05.20	Camurus' Buvidal® Reimbursed in Sweden for the Treatment of Opioid Dependence (PR Newswire)
14.05.20	Camurus' Buvidal® Reimbursed in Sweden for the Treatment of Opioid Dependence (PR Newswire)
07.05.20	Camurus' Interim Report January-March 2020 (PR Newswire)
07.05.20	Camurus' Interim Report January-March 2020 (PR Newswire)
02.04.20	Camurus Announces Strong First Quarter Demand for Buvidal® (PR Newswire)
02.04.20	Camurus Announces Strong First Quarter Demand for Buvidal® (PR Newswire)
26.11.19	Camurus Announces New Study Results Showing Superior Patient Reported Outcomes With Buvidal® Versus Standard of Care in Treatment of Opioid Dependence (PR Newswire)
26.11.19	Camurus Announces New Study Results Showing Superior Patient Reported Outcomes With Buvidal® Versus Standard of Care in Treatment of Opioid Dependence (PR Newswire)
08.11.19	Camurus Announces That FDA Grants Braeburn's Citizen Petition, Eliminating the Risk of Further Blocking of Brixadi™ From the US market (PR Newswire)
08.11.19	Camurus Announces That FDA Grants Braeburn's Citizen Petition, Eliminating the Risk of Further Blocking of Brixadi™ From the US market (PR Newswire)
26.08.19	Camurus: Australian Minister for Health Announced PBS Listing of Buvidal® Weekly and Monthly for Treatment of Opioid Dependence (PR Newswire)
26.08.19	Camurus: Australian Minister for Health Announced PBS Listing of Buvidal® Weekly and Monthly for Treatment of Opioid Dependence (PR Newswire)
23.07.19	Camurus Announces Positive Outcome of U.S. Court Proceeding About Final Approval of Brixadi™ (PR Newswire)
23.07.19	Camurus Announces Positive Outcome of U.S. Court Proceeding About Final Approval of Brixadi™ (PR Newswire)
16.07.19	Ra Pharmaceuticals and Camurus Announce Exclusive License Agreement for FluidCrystal® Extended Release Formulation of Zilucoplan (PR Newswire)
16.07.19	Ra Pharmaceuticals and Camurus Announce Exclusive License Agreement for FluidCrystal® Extended Release Formulation of Zilucoplan (PR Newswire)
20.06.19	Camurus Receives IND Acceptance From the FDA to Enter Phase 3 with CAM2029 for Treatment of Acromegaly (PR Newswire)
20.06.19	Camurus Receives IND Acceptance From the FDA to Enter Phase 3 with CAM2029 for Treatment of Acromegaly (PR Newswire)
04.06.19	Camurus Announces Publication of Phase 3 Study Results Showing Long-term Safety, Efficacy and High Rates of Patient Satisfaction With Buvidal® (PR Newswire)
04.06.19	Camurus Announces Publication of Phase 3 Study Results Showing Long-term Safety, Efficacy and High Rates of Patient Satisfaction With Buvidal® (PR Newswire)
09.05.19	Camurus Interim Report January-March 2019 (PR Newswire)
09.05.19	Camurus Interim Report January-March 2019 (PR Newswire)
06.04.19	Positive Treatment Results for Buvidal® in Fentanyl Users Presented at the ASAM 50th Annual Conference (PR Newswire)
06.02.19	Camurus - Full Year Report 2018 (PR Newswire)
01.02.19	Camurus to Present Full Year 2018 Results on 6 February (PR Newswire)
23.12.18	Camurus AB: US FDA Issues A Tentative Approval of Brixadi™ (buprenorphine) Extended-release Injection for Treatment of Opioid Use Disorder (PR Newswire)
28.11.18	Buvidal® Weekly and Buvidal® Monthly (CAM2038) Approved in Australia as the First Long-acting Treatment of Opioid Dependence (PR Newswire)
28.11.18	Buvidal® Weekly and Buvidal® Monthly (CAM2038) Approved in Australia as the First Long-acting Treatment of Opioid Dependence (PR Newswire)
26.11.18	Europeiska kommissionen beviljar godkännande för försäljning för veckovis och månatligt bruk av Buvidal® för opioidberoende (PR Newswire)
22.11.18	The European Commission Grants Camurus Marketing Authorisation for Weekly and Monthly Buvidal® for Opioid Dependence (PR Newswire)
22.11.18	Die Europäische Kommission erteilt die Marktzulassung für wöchentliche und monatliche Buvidal®-Depotinjektionen zur Behandlung von Opioidabhängigkeit (PR Newswire)
22.11.18	The European Commission Grants Marketing Authorisation for Weekly and Monthly Buvidal® for Opioid Dependence (PR Newswire)
22.11.18	Camurus Receives EU Approval for Weekly and Monthly Buvidal® (CAM2038) for Opioid Dependence (PR Newswire)
22.11.18	Camurus Receives EU Approval for Weekly and Monthly Buvidal® (CAM2038) for Opioid Dependence (PR Newswire)
10.10.18	Camurus to Present at Jefferies 2018 London Healthcare Conference (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

CieFinRichemont	137.35	1.40 %	K V
Sonova Hldg	297.30	1.29 %	K V
Logitech Intl	74.86	1.22 %	K V
Nestle	75.22	1.02 %	K V
Alcon	76.32	0.95 %	K V
UBS Group	28.17	-0.67 %	K V
Swiss Re	131.95	-0.68 %	K V
Geberit	533.80	-0.78 %	K V
Lonza Grp	541.40	-0.81 %	K V
Kuehne+Nagel Int	202.60	-1.65 %	K V

Nachrichten zu Camurus AB

Aktien Top/Flop

Meistgelesene Nachrichten